Johnson and Johnson, Aspen ink Covid vaccine manufacturing pact
Durban: South African pharmaceutical company Aspen Pharmacare said it has entered into an agreement with 'Johnson & Johnson' (J&J) for the technical transfer and proposed commercial manufacturing of their Covid-19 vaccine candidate.
The vaccine candidate, Ad26.COV2-S is currently undergoing clinical trials.
Aspen Pharmacare on Monday said it will perform formulation, filling and secondary packaging of the vaccine for supply to Johnson & Johnson.
This agreement is still subject to the successful completion of the relevant technology transfer activities and finalisation of certain commercial manufacturing terms.
"We have been selected as a vaccine partner by Johnson & Johnson and this project will receive priority focus," said Stephen Saad, Aspen Group Chief Executive.
"We are particularly pleased to be given the opportunity of providing assistance for patients in need across the world from our South African base," Saad added.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.